Syk Inhibitor Treats Rheumatoid Arthritis in Trial


Syk Inhibitor R788 proven effective in treating rheumatoid arthritis.

Investigational Syk inhibitor R788 was proven effective in treating rheumatoid arthritis in a study by researchers from Brigham and Women’s Hospital and Harvard Medical School that was published in the New England Journal of Medicine.

The following video describes the study and discusses rheumatoid arthritis. Click here to access this third-party resource.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
© 2024 MJH Life Sciences

All rights reserved.